

August 7, 2014



OPKO to Announce Top Line RAYALDEE Results and Second Quarter 2014 Financial Results on August 11, 2014

MIAMI--(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:[OPK](#)) will announce top line data from the first of two identical pivotal Phase 3 clinical trials for RAYALDEE™ and its second-quarter 2014 financial results on Monday, August 11, 2014, after the market closes. OPKO's senior management team will host a conference call and live audio webcast at 8:30 a.m. ET on Tuesday, August 12, 2014 to discuss the Phase 3 data and the Company's results in greater detail.

The conference call will be available via phone and webcast. The conference call dial-in information is listed below. To access the webcast, please log on to the OPKO website at www.opko.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required. A link to the live webcast is also included below.

CONFERENCE CALL & WEBCAST INFORMATION:

WHEN: Tuesday, August 12, 2014, 8:30 a.m. ET

DOMESTIC & CANADA DIAL-IN: 1-201-689-8562

INTERNATIONAL DIAL-IN: 1-877-407-0789

LIVE WEBCAST LINK: <http://public.viavid.com/index.php?id=110543>

For those unable to participate in the conference call or webcast, a replay will be available beginning August 12, 2014 at 11:30 a.m. ET until September 12, 2014 at 11:59 p.m. ET. To access the replay, dial 1-877-870-5176 or 1-858-384-5517. The replay passcode is 13588800.

The replay can also be accessed for 30 days on OPKO's website at www.opko.com.

About OPKO Health, Inc.

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.

Investor Relations:

FTI Consulting
Barbara Ryan, 212-850-5679
Managing Director

Barbara.Ryan@fticonsulting.com

or

Media Relations:

Kimberly Ha, 212-850-5612

Senior Director

Kimberly.Ha@fticonsulting.com

Source: OPKO Health, Inc.